Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02925221

Canadian Medical Assessment of JINARC™ Outcomes Registry — C-MAJOR  

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trial

Official title:
Canadian Observational Cohort Study of the Real-life Assessment of Tolvaptan (JINARC™) in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Clinical Trial Summary

This study is part of the Health Canada approval requirement for JINARC™ (tolvaptan) and is an observational, non-interventional study (NIS) describing the impact of tolvaptan on ADPKD-related burden of illness as measured with a set of Patient Reported Outcome (PRO) Questionnaires. The study is also describing the time to renal replacement therapy (RRT), such as dialysis and transplantation, and the long-term mortality rate and causes (i.e. renal and hepatic), in ADPKD patients treated with JINARC™ (tolvaptan)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02925221
Study type Observational
Source Otsuka Canada Pharmaceutical Inc.
Contact Annick Laplante
Phone +1 514-654-8616
Email Annick.Laplante@otsuka-ca.com
Status Recruiting
Phase
Start date January 2016
Completion date June 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT02964273 - Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) Phase 3
Terminated NCT01223755 - Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency Phase 2/Phase 3
Completed NCT01280721 - A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan] Phase 3
Completed NCT01214421 - Tolvaptan Extension Study in Participants With ADPKD Phase 3
Completed NCT02225860 - Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease Phase 2/Phase 3
Active, not recruiting NCT01616927 - Study of Lanreotide to Treat Polycystic Kidney Disease Phase 3
Completed NCT01430494 - Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease N/A
Completed NCT00346918 - Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Completed NCT03949894 - Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease Phase 4
Completed NCT04689074 - Establishment of the Human Intestinal and Salivary Microbiota Biobank - Kidney Diseases
Terminated NCT02616055 - Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 Phase 2
Recruiting NCT06289998 - Study of Tamibarotene in Patients With ADPKD Phase 2
Completed NCT02112136 - Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD N/A
Recruiting NCT02115659 - Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 3
Completed NCT00309283 - Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study Phase 3
Recruiting NCT06345755 - A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants Phase 1